Related Experiment Video
Updated: Feb 6, 2026
05:39
Dermoscopy Aids in the Diagnosis of Discoid Lupus Erythematosus
Published on: May 16, 2025
672
Rapamycin for refractory discoid lupus erythematosus
Mitchell Herold1, Nicholas A Richmond1, Michael A Montuno1
1Department of Dermatology, University of Florida College of Medicine, Gainesville, Florida.
Dermatologic Therapy
|August 16, 2018
Summary
Rapamycin offers a new treatment option for generalized discoid lupus erythematosus resistant to standard therapies. This immunosuppressive drug showed positive results within six weeks with no adverse effects.
Area of Science:
- Immunology
- Dermatology
- Pharmacology
Background:
- Generalized discoid lupus erythematosus (GDLE) presents significant treatment challenges.
- Conventional therapies include photoprotection, corticosteroids, and steroid-sparing immunosuppressants.
- Rapamycin (sirolimus) is an inhibitor of mammalian target of rapamycin (mTOR), impacting cell division and immune responses.
Observation:
- A case of GDLE refractory to multiple conventional treatments (steroids, prednisone, azathioprine, mycophenolate mofetil, hydroxychloroquine, thalidomide) was documented.
- The addition of rapamycin was administered to this refractory case.
- Treatment response and medication tolerance were closely monitored.
Findings:
- Rapamycin administration resulted in a positive treatment response for GDLE within six weeks.
- The patient exhibited good tolerance to rapamycin.
- No adverse effects were reported during the treatment period.
Implications:
- Rapamycin may be a viable therapeutic option for severe or generalized discoid lupus erythematosus unresponsive to established treatments.
- Further investigation into rapamycin's efficacy and safety in refractory autoimmune connective tissue diseases is warranted.
- This finding expands the therapeutic armamentarium for difficult-to-treat lupus erythematosus subtypes.
